Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis

Amir A. Rahnemai-Azar, Allison Weisbrod, Mary Dillhoff, Carl Schmidt, Timothy M. Pawlik

Research output: Contribution to journalReview article

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver tumor with increasing incidence worldwide. The outcome of patients with iCCA is dismal owing to tumor's aggressiveness, late diagnosis and lack of effective treatment options. Detection of the tumor at early stages may make surgical resection, as only potential curative treatment, more feasible. Unfortunately, despite recent developments in imaging modalities and laboratory tests, the diagnosis of iCCA remains challenging and patients often present in advanced stages when surgery cannot be offered. Moreover, accurate assessment of disease burden is critical to optimize management strategy, including the use of adjuvant therapies and clinical trials. Identifying iCCA specific diagnostic and prognostic biomarkers has been a focus of interest among many investigators with a progressive increase in data on iCCA related to advances in “omics” technologies. We herein summarize iCCA biomarkers and define the molecular mechanisms underlying iCCA carcinogenesis, as well as highlight potential diagnostic and prognostic application of molecular biomarkers.

Original languageEnglish (US)
Pages (from-to)125-137
Number of pages13
JournalSurgical Oncology
Volume26
Issue number2
DOIs
StatePublished - Jun 1 2017

Fingerprint

Cholangiocarcinoma
Biomarkers
Neoplasms
Clinical Laboratory Techniques
Delayed Diagnosis
Carcinogenesis
Therapeutics
Research Personnel
Clinical Trials
Technology
Liver
Incidence

Keywords

  • Biliary tract cancer
  • Biomarkers
  • Diagnosis
  • Intrahepatic cholangiocarcinoma
  • Molecular pathogenesis
  • Prognosis

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Rahnemai-Azar, A. A., Weisbrod, A., Dillhoff, M., Schmidt, C., & Pawlik, T. M. (2017). Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surgical Oncology, 26(2), 125-137. https://doi.org/10.1016/j.suronc.2016.12.009

Intrahepatic cholangiocarcinoma : Molecular markers for diagnosis and prognosis. / Rahnemai-Azar, Amir A.; Weisbrod, Allison; Dillhoff, Mary; Schmidt, Carl; Pawlik, Timothy M.

In: Surgical Oncology, Vol. 26, No. 2, 01.06.2017, p. 125-137.

Research output: Contribution to journalReview article

Rahnemai-Azar, AA, Weisbrod, A, Dillhoff, M, Schmidt, C & Pawlik, TM 2017, 'Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis', Surgical Oncology, vol. 26, no. 2, pp. 125-137. https://doi.org/10.1016/j.suronc.2016.12.009
Rahnemai-Azar AA, Weisbrod A, Dillhoff M, Schmidt C, Pawlik TM. Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis. Surgical Oncology. 2017 Jun 1;26(2):125-137. https://doi.org/10.1016/j.suronc.2016.12.009
Rahnemai-Azar, Amir A. ; Weisbrod, Allison ; Dillhoff, Mary ; Schmidt, Carl ; Pawlik, Timothy M. / Intrahepatic cholangiocarcinoma : Molecular markers for diagnosis and prognosis. In: Surgical Oncology. 2017 ; Vol. 26, No. 2. pp. 125-137.
@article{3f77c26462e241ac91cf7fef172fc270,
title = "Intrahepatic cholangiocarcinoma: Molecular markers for diagnosis and prognosis",
abstract = "Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver tumor with increasing incidence worldwide. The outcome of patients with iCCA is dismal owing to tumor's aggressiveness, late diagnosis and lack of effective treatment options. Detection of the tumor at early stages may make surgical resection, as only potential curative treatment, more feasible. Unfortunately, despite recent developments in imaging modalities and laboratory tests, the diagnosis of iCCA remains challenging and patients often present in advanced stages when surgery cannot be offered. Moreover, accurate assessment of disease burden is critical to optimize management strategy, including the use of adjuvant therapies and clinical trials. Identifying iCCA specific diagnostic and prognostic biomarkers has been a focus of interest among many investigators with a progressive increase in data on iCCA related to advances in “omics” technologies. We herein summarize iCCA biomarkers and define the molecular mechanisms underlying iCCA carcinogenesis, as well as highlight potential diagnostic and prognostic application of molecular biomarkers.",
keywords = "Biliary tract cancer, Biomarkers, Diagnosis, Intrahepatic cholangiocarcinoma, Molecular pathogenesis, Prognosis",
author = "Rahnemai-Azar, {Amir A.} and Allison Weisbrod and Mary Dillhoff and Carl Schmidt and Pawlik, {Timothy M.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.suronc.2016.12.009",
language = "English (US)",
volume = "26",
pages = "125--137",
journal = "Surgical Oncology",
issn = "0960-7404",
publisher = "Elsevier BV",
number = "2",

}

TY - JOUR

T1 - Intrahepatic cholangiocarcinoma

T2 - Molecular markers for diagnosis and prognosis

AU - Rahnemai-Azar, Amir A.

AU - Weisbrod, Allison

AU - Dillhoff, Mary

AU - Schmidt, Carl

AU - Pawlik, Timothy M.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver tumor with increasing incidence worldwide. The outcome of patients with iCCA is dismal owing to tumor's aggressiveness, late diagnosis and lack of effective treatment options. Detection of the tumor at early stages may make surgical resection, as only potential curative treatment, more feasible. Unfortunately, despite recent developments in imaging modalities and laboratory tests, the diagnosis of iCCA remains challenging and patients often present in advanced stages when surgery cannot be offered. Moreover, accurate assessment of disease burden is critical to optimize management strategy, including the use of adjuvant therapies and clinical trials. Identifying iCCA specific diagnostic and prognostic biomarkers has been a focus of interest among many investigators with a progressive increase in data on iCCA related to advances in “omics” technologies. We herein summarize iCCA biomarkers and define the molecular mechanisms underlying iCCA carcinogenesis, as well as highlight potential diagnostic and prognostic application of molecular biomarkers.

AB - Intrahepatic cholangiocarcinoma (iCCA) is the second most common primary liver tumor with increasing incidence worldwide. The outcome of patients with iCCA is dismal owing to tumor's aggressiveness, late diagnosis and lack of effective treatment options. Detection of the tumor at early stages may make surgical resection, as only potential curative treatment, more feasible. Unfortunately, despite recent developments in imaging modalities and laboratory tests, the diagnosis of iCCA remains challenging and patients often present in advanced stages when surgery cannot be offered. Moreover, accurate assessment of disease burden is critical to optimize management strategy, including the use of adjuvant therapies and clinical trials. Identifying iCCA specific diagnostic and prognostic biomarkers has been a focus of interest among many investigators with a progressive increase in data on iCCA related to advances in “omics” technologies. We herein summarize iCCA biomarkers and define the molecular mechanisms underlying iCCA carcinogenesis, as well as highlight potential diagnostic and prognostic application of molecular biomarkers.

KW - Biliary tract cancer

KW - Biomarkers

KW - Diagnosis

KW - Intrahepatic cholangiocarcinoma

KW - Molecular pathogenesis

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85013680737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013680737&partnerID=8YFLogxK

U2 - 10.1016/j.suronc.2016.12.009

DO - 10.1016/j.suronc.2016.12.009

M3 - Review article

C2 - 28577718

AN - SCOPUS:85013680737

VL - 26

SP - 125

EP - 137

JO - Surgical Oncology

JF - Surgical Oncology

SN - 0960-7404

IS - 2

ER -